The clinical value of maintenance in multiple myeloma

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 25 Jun 2021
Views: 2078
Rating:
Save
Prof Wee Joo Chng - National University of Singapore, Singapore

Prof Wee Joo Chng speaks to ecancer about the clinical value of maintenance in multiple myeloma. Initially, he mentions the maintenance treatments he recommends for multiple myeloma patients.

Prof Chng also gives different regimen recommendation for high-risk cytogenetics patients. He discusses the phase 3 TOURMALINE-MM4 trial investigating ixazomib vs placebo as post-induction maintenance therapy in newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT).

Prof Chng also talks about the measurable residual disease (MRD) evaluation during ixazomib (IXA) maintenance in newly diagnosed multiple myeloma (NDMM). In the end, he discusses what patient profile should receive maintenance treatments (for both the transplant eligible and ineligible) and the impact of the TOURMALINE MM3 and MM4 data in clinical practice.

 

Types of maintenance treatments for MM patients
Treatment recommendation for high-risk cytogenetics patients
Patient profile that should receive maintenance treatments (for both the transplant eligible and ineligible)
Impact of the TOURMALINE MM3 and MM4 data in clinical practice
Significance of the MM4 trial data

This programme has been supported by an unrestricted educational grant from Takeda.

Related Videos

Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly wit...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab shows complete molecular response for patients with P...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration in combination with pomalidomide-dexameth...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022
A single dose of ctx001 shows promising efficacy and safety for TDT and severe S...
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy
A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD ( Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy )
13 Jun 2022
Treatment with decitabine resulted in a similar survival and fewer adverse event...
Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML ( Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany )
13 Jun 2022